Year-end report – ProstaLund AB (publ)

• Net sales reached SEK 6,4 (5,6) million, an increase of 16,1 percent
• Operating loss amounted to SEK -3,4 (-3,1) million
• The operating result includes one-time costs of approximately SEK 2 million related to organizational changes
• Loss after taxes SEK -3,4 (-3,1) million
• Earnings per share, SEK (basic and diluted) amounted to SEK -0,04 (-0,05)
• Cash flow from operating activities amounted to SEK -5,6 (-3,2) million

Significant events during period

• Extraordinary general meeting on October 12th – New election of Per Langö, Tomas Eriksson, Paul de Potocki and Tom Rönnlund as regular board members and re-election of Marianne Östlund and Annette Colin as regular board members
• Per Langö elected as chairman of the board on October on 12th
• Anders Kristensson appointed as new CEO on October 27th
• New election committee appointed on November 29th
• Niclas Nyström appointed new CFO on December 6th
• Agreement with Esbjerg Sygehus in Denmark

1 January-31 December

• Net sales reached SEK 22,2 (17,4), an increase of 27,5 percent
• Operating loss amounted to SEK -16,9 (-10,9) million
• The operating result includes one-time costs of approximately SEK 4 million related to organizational changes
• Loss after taxes amounted to SEK -17,0 (-11,1) million
• Earnings per share, SEK (basic and diluted) amounted to SEK -0,25 (-0,21)
• Cash flow from operating activities amounted to SEK -23,8 (-16,2) million
• Cash and cash equivalents amounted to SEK 15,4 (12,3) million per December 31st 2023

Significant events after the end of the period

• New management team appointed on February 15th